PubRank

Illana Gozes

Author PubWeight™ 68.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012 1.64
2 A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008 1.41
3 Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003 1.38
4 Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007 1.30
5 NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009 1.26
6 Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007 1.24
7 Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 2006 1.14
8 A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 2004 1.12
9 Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 2007 1.12
10 Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 2006 1.08
11 PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci 2005 1.06
12 PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem 2009 1.03
13 NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002 1.01
14 Neuroprotective protein and carboxypeptidase E. J Mol Neurosci 2009 0.99
15 A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2010 0.98
16 ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci 2008 0.98
17 Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Rev 2006 0.97
18 Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 2004 0.97
19 Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol 2004 0.96
20 Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 2005 0.95
21 Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol 2010 0.95
22 NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis 2013 0.94
23 Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis 2011 0.93
24 NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des 2007 0.92
25 Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004 0.92
26 NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci 2006 0.91
27 The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One 2012 0.90
28 Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem 2012 0.90
29 Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012 0.90
30 Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci 2007 0.89
31 The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 2005 0.88
32 NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol 2009 0.87
33 NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides 2010 0.87
34 The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 2003 0.86
35 Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 2004 0.86
36 Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis 2012 0.86
37 Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci 2009 0.86
38 Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des 2011 0.86
39 Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr Pharm Des 2007 0.85
40 NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther 2006 0.85
41 Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides 2003 0.84
42 Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem 2007 0.84
43 A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sci 2002 0.84
44 NAP protects hippocampal neurons against multiple toxins. Peptides 2007 0.83
45 (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci 2002 0.83
46 The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay. Hypertens Pregnancy 2005 0.82
47 The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem 2009 0.82
48 Antagonism of VIP-stimulated cyclic AMP formation in chick brain. J Mol Neurosci 2003 0.81
49 The effects of vascular intrauterine growth retardation on cortical astrocytes. J Matern Fetal Neonatal Med 2010 0.81
50 VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides 2006 0.81
51 Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides 2013 0.81
52 Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J Pept Sci 2008 0.81
53 Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci 2006 0.81
54 New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy 2014 0.81
55 NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) 2009 0.80
56 Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides 2005 0.80
57 Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs 2007 0.80
58 Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 2005 0.79
59 Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. J Mol Neurosci 2007 0.79
60 A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. J Mol Neurosci 2008 0.79
61 D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J Mol Neurosci 2012 0.79
62 3R tau expression modifies behavior in transgenic mice. J Neurosci Res 2010 0.78
63 A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci 2002 0.78
64 Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport 2003 0.78
65 VIP and PACAP: novel approaches to brain functions and neuroprotection. Curr Pharm Des 2011 0.77
66 Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. J Neural Transm (Vienna) 2008 0.76
67 Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. Am J Obstet Gynecol 2002 0.76
68 Apolipoprotein E knockout mice as a model of behavioral dysfunction. J Mol Neurosci 2004 0.76
69 The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. Biol Chem 2016 0.76
70 Brain injury-dependent expression of activity-dependent neuroprotective protein. J Mol Neurosci 2004 0.76
71 In vitro and in vivo treatment of colon cancer by VIP antagonists. Regul Pept 2002 0.76
72 The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides 2005 0.75
73 The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. Regul Pept 2002 0.75
74 A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. Ann N Y Acad Sci 2006 0.75
75 Novel analogs of VIP with multiple C-terminal domains. Peptides 2007 0.75
76 Novel extended and branched N-terminal analogs of VIP. Regul Pept 2006 0.75
77 Inge Grundke-Iqbal, Ph.D. (1937–2012): the discoverer of the abnormal hyperphosphorylation of tau in Alzheimer’s disease. J Mol Neurosci 2013 0.75
78 8th international symposium on VIP, PACAP related peptides. Introduction. J Mol Neurosci 2008 0.75
79 Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. J Mol Neurosci 2005 0.75
80 Protein synthesis in nuclei: when did the story start? J Mol Neurosci 2002 0.75
81 Summer neuropeptide conference. The 3rd joint meeting of the summer neuropeptide conference (13th annual meeting) and the European Neuropeptide Club (13th annual meeting) Montauk, NY, June 8-12, 2003. Neuropeptides 2003 0.75
82 Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection. J Mol Neurosci 2004 0.75
83 The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley. Expert Opin Ther Targets 2007 0.75
84 Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmol 2011 0.75
85 In memory of our teacher, Dr. Akira Arimura. J Mol Neurosci 2008 0.75